antitrypsin deficiency

an·ti·tryp·sin de·fi·cien·cy

deficiency of α1-antitrypsin, a serum protease inhibitor, is associated with emphysema and/or liver cirrhosis. By isoelectric focusing, numerous variants have been identified, with different levels of normal activity; autosomal recessive inheritance, caused by mutation in the P1 gene on chromosomal 14q.
References in periodicals archive ?
for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases such as non-cystic fibrosis bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD) and primary ciliary dyskinesia (PCD).
Adverum Biotechnologies announced the completion of dosing and evaluation of patients in the first cohort of the ADVANCE Phase 1/2 clinical trial for alpha-1 antitrypsin deficiency.
POL6014 is a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF), as well as other neutrophilic pulmonary diseases, such as non-cystic fibrosis bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD) and primary ciliary dyskinesia (PCD).
Under the exclusive license the company plans to conduct a Phase II study for the treatment of alpha-1 antitrypsin deficiency, a congenital orphan condition.
Respreeza is the only therapy in a clinical study to slow the progression of lung disease caused by genetic condition Alpha 1 antitrypsin deficiency.
The other diseases covered by the tests are celiac disease, alpha-1 antitrypsin deficiency, early onset primary dystonia, Factor XI deficiency, Gaucher disease type 1, glucose-6-Phosphate Dehydrogenase deficiency (also known as G6PD), hereditary hemochromatosis, and hereditary thrombophilia.
Global Markets Direct's, 'Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2016', provides an overview of the Alpha- Antitrypsin Deficiency pipeline landscape.
The increasing pervasiveness of people with alpha-1 antitrypsin deficiency (AATD) disorder, and hence, the increased demand for biological drugs is the major fueling factor for the growth of the alpha-1 antitrypsin drugs market in this region.
USPRwire, Mon Oct 26 2015] Global Markets Direct's, 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2015', provides an overview of the Alpha- Antitrypsin Deficiency's therapeutic pipeline.
The lady was suffering from alpha 1 antitrypsin deficiency.
Alpha-1 antitrypsin deficiency is a common genetic cause of both liver and lung disease affecting an estimated 3.
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.